iSpheric gains US approval

Article

The iSpheric Model YA-60BB intraocular lens (IOL) (Hoya) has received FDA approval.

The iSpheric Model YA-60BB intraocular lens (IOL) (Hoya) has received FDA approval.

The foldable hydrophobic IOL, which is already available in Europe and Asia, features a blue-light blocker and can be implanted through an un-enlarged incision. In a clinical trial, 98% of the 600 enrolled subjects reported best corrected visual acuity (BCVA) of ≥20/40 from one-month postoperatively until the final 12-month follow-up visit. No significant adverse events were reported.

The iSpheric will have its official launch at this year's American Academy of Ophthalmology (AAO) meeting, which will be held November 8–11 in Atlanta, GA, US. The lens will be shipped to facilities in the US by the end of the year, and a new version, available in the iSert pre-loaded injector system, will be available in early 2009.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.